Mozaheb Zahra, Hasanzadeh NazarAbadi Mohamad Hasan, Aghaee Monavar Afzal
Department of hematology-oncology, Mashhad University of Medical Science, Iran.
Asian Pac J Cancer Prev. 2012;13(7):3009-13. doi: 10.7314/apjcp.2012.13.7.3009.
The clinical course of individual chronic lymphocytic leukemia (CLL) is highly variable and clinical staging systems do not help us to predict if and at what rate there will be disease progression in an individual patient diagnosed with early stage disease. Recently, several important observations related to other prognostic factors including lymphocyte doubling time (LDT), β2-microglobulin (β2-MG), and percent of smudge cell in peripheral blood smears, cytogenetic and molecular analysis have been made. The aim of this study was to evaluate a range of prognostic factors in our CLL patients.
Seventy patients with CLL were enrolled. Prognostic factors of disease including Binet staging, LDT, β2-MG, ESR, LDH, percent of smudge cell in peripheral blood smear, absolute lymphocyte count, and conventional cytogenetic (CC) analysis were evaluated at diagnosis, and the patients were followed up to determine their outcome. We compared factors with each other and with Binet staging and prognosis.
Enrolled patients aged 37-85 years at diagnosis or during follow up. There was no relationship between serum LDH level (P=0.3), ESR (P=0.11), percent of smudge cells in peripheral blood smear (P=0.94), and absolute lymphocyte count (P=0.18) with the stage of disease and prognosis, but the β2 macroglobulin level (p<0.0001), LDT (p<0.001) had direct and significant relation with staging and outcome. In 19% of patients cytogenetic alteration were seen.
The detection of cytogenetic alteration only using the CC method is not sufficient and we need to use FISH, but because FISH study is an expensive method not available in all areas, we believe that β2 MG can be applied in its place as a good prognostic factor for CLL at diagnosis and during follow up. We suggest to add it to Binet staging for prognostic subgrouping of CLL.
个体慢性淋巴细胞白血病(CLL)的临床病程高度可变,临床分期系统无法帮助我们预测确诊为早期疾病的个体患者是否会出现疾病进展以及进展速度如何。最近,人们对包括淋巴细胞倍增时间(LDT)、β2-微球蛋白(β2-MG)、外周血涂片涂抹细胞百分比、细胞遗传学和分子分析等其他预后因素进行了一些重要观察。本研究的目的是评估我们的CLL患者的一系列预后因素。
招募了70例CLL患者。在诊断时评估疾病的预后因素,包括Binet分期、LDT、β2-MG、血沉(ESR)、乳酸脱氢酶(LDH)、外周血涂片涂抹细胞百分比、绝对淋巴细胞计数和传统细胞遗传学(CC)分析,并对患者进行随访以确定其预后。我们将这些因素相互比较,并与Binet分期和预后进行比较。
入选患者诊断时或随访期间年龄为37 - 85岁。血清LDH水平(P = 0.3)、ESR(P = 0.11)、外周血涂片涂抹细胞百分比(P = 0.94)和绝对淋巴细胞计数(P = 0.18)与疾病分期和预后无关,但β2微球蛋白水平(p < 0.0001)、LDT(p < 0.)与分期和预后有直接且显著的关系。19%的患者出现细胞遗传学改变。
仅使用CC方法检测细胞遗传学改变是不够的,我们需要使用荧光原位杂交(FISH),但由于FISH研究是一种昂贵的方法,并非所有地区都能开展,我们认为β2 MG可作为CLL诊断和随访期间的良好预后因素替代FISH。我们建议将其添加到Binet分期中,用于CLL的预后亚组划分。